| 17.33 0.5 (2.97%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24  |
1-year : | 27.65 |
| Resists | First : | 20.55 |
Second : | 23.68 |
| Pivot price | 17.72 |
|||
| Supports | First : | 15.48 | Second : | 12.88 |
| MAs | MA(5) : | 16.94  |
MA(20) : | 18.44 |
| MA(100) : | 22.16 |
MA(250) : | 18.54 |
|
| MACD | MACD : | -1.3 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 26.7 |
D(3) : | 23.3 |
| RSI | RSI(14): 39.3 |
|||
| 52-week | High : | 45 | Low : | 7.65 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LYEL ] has closed above bottom band by 41.4%. Bollinger Bands are 32.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.43 - 17.5 | 17.5 - 17.56 |
| Low: | 16.38 - 16.46 | 16.46 - 16.54 |
| Close: | 17.2 - 17.32 | 17.32 - 17.45 |
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Tue, 19 May 2026
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL) - Yahoo Finance
Tue, 12 May 2026
Lyell Immunopharma Announces Participation in May Investor Conferences - GlobeNewswire
Wed, 06 May 2026
Lyell Immunopharma: Q1 Earnings Snapshot - kens5.com
Wed, 06 May 2026
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 - GlobeNewswire
Wed, 06 May 2026
Lyell Immunopharma (NASDAQ: LYEL) trims Q1 loss and advances CAR T trials - Stock Titan
Wed, 06 May 2026
Lyell starts Phase 3 lymphoma dosing, says cash runway reaches Q3 2027 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -65 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 2.333e+007 (%) |
| Held by Institutions | 1.039e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 31000 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -13.62 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 213 % |
| Return on Equity (ttm) | 50 % |
| Qtrly Rev. Growth | -80.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.7475e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -1.28 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 1.34e+006 |
| Forward Dividend | 1.14e+006 |
| Dividend Yield | 7732260% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|